Showing 1 - 10 of 1,194
Persistent link: https://www.econbiz.de/10011971936
As the innovation process of pharmaceuticals is a long, risky and very costly business, economists typically emphasise lack of profit incentives and small market size as the most important obstacles to child-related innovative activity. Moreover, there are ethical concerns because children are...
Persistent link: https://www.econbiz.de/10010297374
Children are therapeutic orphans and an underprivileged group in innovations derived from drug therapy. As the innovation process of pharmaceuticals is a long, risky and very costly business, economists typically emphasise lack of profit incentives and small market size as the most important...
Persistent link: https://www.econbiz.de/10010262984
Persistent link: https://www.econbiz.de/10010208339
Persistent link: https://www.econbiz.de/10010208340
Persistent link: https://www.econbiz.de/10003926907
Children are therapeutic orphans and an underprivileged group in innovations derived from drug therapy. As the innovation process of pharmaceuticals is a long, risky and very costly business, economists typically emphasise lack of profit incentives and small market size as the most important...
Persistent link: https://www.econbiz.de/10002509901
Persistent link: https://www.econbiz.de/10002137134
Persistent link: https://www.econbiz.de/10013179387
The history of pediatric medical research has been characterized as a history of child abuse. Usually, the debate regarding the use of children in medical research has centered on questions of Autonomy (informed consent) and Beneficence (the best interest of the child based on a benefit risk...
Persistent link: https://www.econbiz.de/10014202971